

GENSIGHT BIOLOGICS
A French Société Anonyme (corporation)
with share capital of 718,113.53 Euros
74 rue du Faubourg Saint Antoine
75012 Paris
751 164 757 - Paris Trade and Companies Registry

**NOMINEES TO THE BOARD OF DIRECTORS, GENERAL MEETING OF JUNE 11,
2019**

USUAL NAME: Simone Seiter

PERSONAL HOME ADDRESS: Schillerstr.29 - 61350 Bad Homburg Germany

DATE AND PLACE OF BIRTH: 12/22/1966 – Offenburg Germany

OFFICES THAT EXPIRED IN THE LAST FIVE YEARS IN OTHER COMPANIES :

Simone Seiter, M.D., Ph.D. has served as a director since April 2017. Dr. Seiter has worked as a Vice President with IQVIA (formerly QuintilesIMS) based in Frankfurt, Germany from 2006 to 2019. Prior to joining IQVIA she worked at Capgemini as a consultant for six years and served as a postdoctoral Fellow at the National Institutes of Health (United States) for two years. Previously, Dr. Seiter worked at the Universities of Heidelberg and Homburg, Germany as board certified dermatologist. Dr. Seiter holds an M.D. Ph.D. degree from the University of Heidelberg and an MBA from the University of Applied Sciences in Neu-Ulm Germany.

OFFICES IN THE COMPANY:

Independent member of the Board of Directors, Chair of the Compensation Committee, Member of the Audit Committee

NUMBER OF SHARES OF THE CORPORATION OWNED: 0

GENSIGHT BIOLOGICS
A French Société Anonyme (corporation)
with share capital of 718,113.53 Euros
74 rue du Faubourg Saint Antoine
75012 Paris
751 164 757 - Paris Trade and Companies Registry

**NOMINEES TO THE BOARD OF DIRECTORS, GENERAL MEETING OF JUNE 11,
2019**

USUAL NAME: Maritza McIntyre, PhD

PERSONAL HOME ADDRESS: 13512 Oriental Street, Rockville, Maryland 20853 USA

DATE AND PLACE OF BIRTH: 05/14/1965 - Detroit, Michigan USA

OFFICES THAT EXPIRED IN THE LAST FIVE YEARS IN OTHER COMPANIES:

Maritza C. McIntyre, Ph.D. is the President of Advanced Therapies Partners, LLC.

Dr. McIntyre has 20 years of experience in the development, evaluation and regulation of biological and small molecule products within startup biotech firms, the Food and Drug Administration (FDA), and as a consultant. Dr. McIntyre was a product reviewer and ultimately Branch Chief in the Division of Cellular and Gene Therapies at FDA/CBER, where she was actively involved policy development and liaison activities to stakeholder groups. She has since worked in regulatory affairs and product development at Bavarian Nordic, REGENXBIO, Inc. and NanoCor Therapeutics. She served as Executive Vice President of Regulatory Affairs and Product Development at Bamboo Therapeutics where, as part of the senior management team, she participated in portfolio selection, product development and fundraising that resulted in an initial \$50 million finance round and ultimate the sale of the company to Pfizer.

As president of Advanced Therapies Partners LLC, Dr. McIntyre provides strategic regulatory and product development advice to biotech companies, academics, and venture capital firms. She has proven success in defining development strategies for products with complex regulatory challenges including special designations (orphan, RMAT, pediatric orphan drug designation), endpoint selection, accelerated approval, complete response letters and dispute resolution. She has also been involved in the preparation of some of the first BLA and MAA submissions for gene therapy products to FDA and EMA. She has multidisciplinary experience, including chemistry manufacturing and control (CMC), preclinical, and clinical with a wide range of product types, including novel gene and cell therapy products, vaccines, biological products and small molecules at varied stages of product development.

Through her participation in industry associations, including ASGCT and the Standards Coordinating Body she has continued to contribute to gene therapy regulatory policy development.

Dr. McIntyre received a Ph.D. in virology from the University of Chicago and graduated magna cum laude with an Honors B.S. in biology from Wayne State University.

OFFICES IN THE COMPANY: None

NUMBER OF SHARES OF THE CORPORATION OWNED: 0

GENSIGHT BIOLOGICS
A French Société Anonyme (corporation)
with share capital of 718,113.53 Euros
74 rue du Faubourg Saint Antoine
75012 Paris
751 164 757 - Paris Trade and Companies Registry

**NOMINEES TO THE BOARD OF DIRECTORS, GENERAL MEETING OF JUNE 11,
2019**

LEGAL CORPORATE NAME: Bpifrance Participations

REGISTERED OFFICE: 27-31 avenue du Général Leclerc – 94710 Maisons-Alfort Cedex

RCS: 509 584 074

REGISTRATION DATE: 08/09/2013

COMPANY PURPOSE: Sustain small and medium-sized enterprises, midsize businesses and innovative businesses in support of state and regional public policies

OFFICES IN THE COMPANY: Member of the Board of Directors, Member of the Nominations Committee, Member of the Audit Committee

NUMBER OF SHARES OF THE CORPORATION OWNED: 2,000,000

GENSIGHT BIOLOGICS
A French Société Anonyme (corporation)
with share capital of 718,113.53 Euros
74 rue du Faubourg Saint Antoine
75012 Paris
751 164 757 - Paris Trade and Companies Registry

**NOMINEES TO THE BOARD OF DIRECTORS, GENERAL MEETING OF JUNE 11,
2019**

LEGAL CORPORATE NAME: Sofinnova Partners SAS

REGISTERED OFFICE: 7/11 Boulevard Haussman – 75009 Paris

RCS: 413 388 596

REGISTRATION DATE: 08/25/1997

COMPANY PURPOSE: Sofinnova Partners is an independent venture capital firm, a European leader in funding for start-ups, early-stage companies, corporate spin-offs and occasionally turnaround situations

OFFICES IN THE COMPANY: None

NUMBER OF SHARES OF THE CORPORATION OWNED: 3,921,568

INFORMATION REGARDING THE EXPECTED PERMANENT REPRESENTATIVE

USUAL NAME: Cédric Moreau

PERSONAL HOME ADDRESS: Sofinnova Partners - 7/11 Boulevard Haussman – 75009 Paris

DATE AND PLACE OF BIRTH: 07/15/1976 - Clamart

OFFICES THAT EXPIRED IN THE LAST FIVE YEARS IN OTHER COMPANIES:

Cedric joined Sofinnova Partners in June 2018 and brings 18 years of experience in life sciences investment banking. He brings to the Sofinnova Crossover team his transactional expertise in

the biopharma industry, with an extensive network of Key Opinion Leaders (KOLs), bankers and lawyers.

Cedric joined from Oddo BHF where he was Managing Director and Head of Healthcare at the Corporate Finance department. In 2017, Oddo BHF was top ranked in the European biotech equity capital market deals league tables. Prior to this, he was Director at Bryan Garnier & Co where he completed several sizeable cross border transactions. In total, he has managed transactions (IPO/ FOn/ PIPEs) in European healthcare companies totaling around €2bn in value. He is well known to the Sofinnova team having executed several mandates for portfolio companies. Before his corporate finance career, he spent 10 years as a Healthcare Equity Analyst and was several times EXTEL top ranked (awarded for both individual and team performances) at Natixis and Fortis. He was in charge of both listed biotech and pharma companies coverage. He brings to the Crossover team his transactional expertise in the biopharma industry, with an extensive network of Key Opinion Leaders (KOLs), bankers and lawyers.

Cedric holds a Master's in Economics and post-graduate diploma in Finance and Taxation (Sorbonne) and Diploma from the Société Française des Analystes Financiers (SFAF).

OFFICES IN THE COMPANY: None

NUMBER OF SHARES OF THE CORPORATION OWNED: 0